Elastin with anti-wrinkle activity and preparation method and application thereof

By fusing laminin with the initial elastin and using Pichia cerevisia expression technology, the problem of poor repair and anti-wrinkle effects of artificial elastin was solved, and significant improvement of cell activity and anti-wrinkle effects in human applications were achieved.

CN118530376BActive Publication Date: 2024-11-26INTERFIELD (CHENGDU) BIOLOGICAL PROD CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411012422.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-26
Estimated Expiration
2044-07-26

AI Technical Summary

Technical Problem

The existing artificial elastin has poor repair and anti-wrinkle effects, and the naturally extracted elastin has problems such as low purity, large molecular weight, unevenness, and risk of carrying viruses and immunogenicity.

Method used

By connecting laminin to the N-terminal or C-terminal of the initial elastin through a flexible linker, its amino acid sequence is optimized to obtain elastin with both repair and anti-wrinkle activities, and efficiently expressed and purified using Pichia cerevisiae expression technology , forming a fusion protein between elastin and laminin.

Benefits of technology

It significantly improves cell proliferation, cell adhesion and cell migration activities, achieves significant anti-wrinkle repair effects, and demonstrates good safety and effects in human applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118530376B_ABST
    Figure CN118530376B_ABST
Patent Text Reader

Abstract

The present application discloses an elastin protein with repair and anti-wrinkle activity and its preparation method and application, which relates to the field of recombinant protein technology and aims to solve the technical problem that the existing artificial elastin protein has poor repair and anti-wrinkle effects. The elastin protein with both repair and anti-wrinkle activity is obtained by connecting laminin to the N-terminus or C-terminus of the initial elastin protein through a flexible linker; the protein sequence of the laminin protein is shown in SEQ ID No.9.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of recombinant protein technology, and in particular to an elastin protein with anti-wrinkle repairing activity and a preparation method and application thereof. Background Art

[0002] Elastin has broad application prospects in the fields of medicine, beauty, cosmetics and health products, but the difficulty of naturally extracted elastin is that the protein purity is low, the molecular weight is large, and it is not uniform, making it difficult to form large-scale production. Products extracted from animals have limitations such as low purity, the risk of carrying viruses, the risk of immunogenicity, and high cost.

[0003] Artificial elastin is similar to natural elastin, has good cell compatibility, can be degraded into natural amino acids in the body, and has low immune rejection. In recent years, artificial elastin has become a highlight in the field of biomedical materials. As the value of ELP's wide application becomes increasingly apparent, the high-throughput expression of artificial elastin in heterologous bodies has become one of the bottleneck issues in its application. Summary of the invention

[0004] The present application provides an elastin with repair and anti-wrinkle activity and a preparation method and application thereof, which at least solves the technical problem that the existing artificial elastin has poor repair and anti-wrinkle effects.

[0005] To solve the above technical problems, the embodiments of the present application provide: an elastin-like protein having both repair and anti-wrinkle activities, wherein the elastin-like protein having both repair and anti-wrinkle activities is obtained by connecting laminin to the N-terminus or C-terminus of the initial elastin-like protein through a flexible linker; the protein sequence of the laminin protein is shown in SEQ ID No.9.

[0006] As some optional embodiments of the present application, when the nucleotide sequence of the initial elastin-like protein is expressed as shown in SEQ ID No. 6, the amino acid sequence of the elastin-like protein having both repair and anti-wrinkle activities is shown in SEQ ID No. 10;

[0007] When the nucleotide sequence of the initial elastin-like protein is expressed as shown in SEQ ID No. 4, the amino acid sequence of the elastin-like protein having both repair and anti-wrinkle activities is shown in SEQ ID No. 12;

[0008] When the nucleotide sequence of the initial elastin-like protein is expressed as shown in SEQ ID No.5, the amino acid sequence of the elastin-like protein having both repair and anti-wrinkle activities is shown in SEQ ID No.14.

[0009] As some optional embodiments of the present application, the nucleotide sequence corresponding to the amino acid sequence shown in SEQ ID No.10 is expressed as shown in SEQ ID No.11;

[0010] The nucleotide sequence corresponding to the amino acid sequence shown in SEQ ID No.12 is expressed as shown in SEQ ID No.13;

[0011] The nucleotide sequence corresponding to the amino acid sequence shown in SEQ ID No.14 is expressed as shown in SEQ ID No.15.

[0012] On the other hand, an embodiment of the present application provides an elastin-like protein with anti-wrinkle activity, wherein the protein sequence of the initial elastin-like protein is [VPGKG(VPGVG)8VPGFG]n, where the number n is ≥1; the nucleotide sequence of the initial elastin-like protein is expressed as shown in any one of SEQ ID No.4, SEQ ID No.5 and SEQ ID No.6.

[0013] As some optional implementations of the present application, the number n is 2, 4 and 8;

[0014] When the number n is 2, the amino acid sequence of the artificial elastin-like protein is as shown in SEQ ID No. 1;

[0015] When n is 4, the amino acid sequence of the artificial elastin-like protein is as shown in SEQ ID No. 2;

[0016] When n is 8, the amino acid sequence of the artificial elastin-like protein is as shown in SEQ ID No.3.

[0017] As some optional embodiments of the present application, the nucleotide sequence corresponding to the amino acid sequence shown in SEQ ID No.1 is expressed as shown in SEQ ID No.4;

[0018] The nucleotide sequence corresponding to the amino acid sequence shown in SEQ ID No.2 is expressed as shown in SEQ ID No.5;

[0019] The nucleotide sequence corresponding to the amino acid sequence shown in SEQ ID No.3 is expressed as shown in SEQ ID No.6.

[0020] In another aspect, the present invention provides a method for preparing the elastin-like protein having both repair and anti-wrinkle activities as described above, comprising the following steps:

[0021] Selecting a LN-5 target gene sequence, and connecting the LN-5 target gene sequence to the N-terminus of a recombinant elastin protein through a flexible linker (GGGGS) 3, wherein the recombinant elastin protein includes a recombinant elastin protein ELP2, a recombinant elastin protein ELP4, or a recombinant elastin protein ELP8; obtaining a repairable recombinant elastin protein sequence as shown in SEQ ID No. 10, SEQ ID No. 12, or SEQ ID No. 14; optimizing and designing based on the repairable recombinant elastin protein sequence to obtain a nucleotide sequence as shown in SEQ ID No. 11, SEQ ID No. 13, or SEQ ID No. 15;

[0022] Based on the nucleotide sequence shown in SEQ ID No.11, SEQ ID No.13 or SEQ ID No.15, a recombinant plasmid of reparative recombinant human elastin is obtained, the recombinant plasmid of reparative recombinant human elastin is subjected to Pichia pastoris electroporation, and cultured until a single colony appears, and a high-copy recombinant yeast engineering strain is obtained by screening; the high-copy recombinant yeast engineering strain is induced to express, and the expressed target protein is obtained; the expressed target protein is purified to obtain an elastin-like protein with both repair and anti-wrinkle activities.

[0023] In another aspect, the present invention provides a method for preparing the elastin-like protein having anti-wrinkle activity as described above, comprising the following steps:

[0024] Based on the elastin-like protein sequences shown in SEQ ID No.1, SEQ ID No.2 and SEQ ID No.3, the nucleotide sequences shown in SEQ ID No.4, SEQ ID No.5 and SEQ ID No.6 were obtained respectively; based on the recombinant elastin-like gene sequences shown in SEQ ID No.4, SEQ ID No.5 and SEQ ID No.6, the recombinant elastin-like plasmids, i.e., pPIC9K-ELP2, pPIC9K-ELP4 and pPIC9K-ELP8, were obtained;

[0025] pPIC9K-ELP2, pPIC9K-ELP4 and pPIC9K-ELP8 were subjected to Pichia pastoris electroporation and cultured until single colonies appeared, and high-copy recombinant yeast engineering strains were screened; the high-copy recombinant yeast engineering strains were induced for expression, and expression of target protein ELP2, expression of target protein ELP4 and expression of target protein ELP8 were obtained respectively;

[0026] The expressed target protein ELP2, the expressed target protein ELP4 and the expressed target protein ELP8 were purified to obtain recombinant elastin ELP2, recombinant elastin ELP4 and recombinant elastin ELP8.

[0027] On the other hand, the embodiment of the present application provides an application of the elastin-like protein having both repair and anti-wrinkle activities as described above, wherein the elastin-like protein having both repair and anti-wrinkle activities is applied to prepare skin care products;

[0028] The skin care product prepared from the elastin-like protein having both repair and anti-wrinkle activities has a specific activity of 28500 U / mg in promoting Hacat cell adhesion;

[0029] The skin care product prepared from the elastin-like protein having both repair and anti-wrinkle activities has a cell proliferation promoting specific activity of 59500 U / mg;

[0030] The skin care product prepared from the elastin-like protein having both repair and anti-wrinkle activities has a Hacat cell migration promoting activity of 46.40%.

[0031] In another aspect, the present application provides an application of the elastin-like protein with anti-wrinkle activity as described above, wherein the initial elastin-like protein is applied to prepare skin care products;

[0032] The skin care product prepared from the initial elastin-like protein has a specific activity of promoting Hacat cell adhesion of 3000U / mg to 6400U / mg;

[0033] The skin care product prepared from the initial elastin-like protein has a cell proliferation promoting activity of 2460U / mg to 9600U / mg;

[0034] The skin care product prepared from the initial elastin-like protein has an activity of promoting Hacat cell migration of 26.57%.

[0035] There is already naturally extracted elastin for sale on the market, which is extracted from bonito. Naturally extracted elastin has a large molecular weight and is not uniform, but it also has certain efficacy. The difficulty of natural extraction is that the content of pure protein is limited, and it is difficult to form large-scale production. Products extracted from animals have limitations such as low product purity, the risk of carrying viruses, the risk of immunogenicity, and high cost. Therefore, it is necessary to express and prepare highly purified humanized elastin in prokaryotic microorganisms or eukaryotic microorganisms through genetic engineering technology. The present application uses genetic engineering technology to recombinantly express laminin functional fragments and elastin domain fragments to obtain a repairable elastin. After in vitro cell verification and human efficacy verification, the repairable elastin has the efficacy of laminin and elastin at the same time, and has significantly improved cell proliferation, promoted cell adhesion and promoted cell migration activity. It can be applied to the field of biological skin care and has obvious anti-wrinkle repair effect. That is, the present application provides a fusion protein of human elastin and laminin expressed by Pichia pastoris, and uses a connecting short peptide linker (GGGGS) to express the elastin pentapeptide repeat sequence and the laminin domain functional region fragment sequence in series. Pichia pastoris expression is endotoxin-free, has a high yield, a simple culture medium, stable expressed protein, and can be secreted to the extracellular space for easy purification. It also has the functions of correctly processing, modifying, and reasonably folding heterologous proteins in space. Therefore, using yeast to express heterologous proteins has great advantages. The fusion protein peptide of the present application has the effects of both elastin and laminin, and has obvious activities in promoting cell proliferation, cell adhesion, and cell migration. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] In order to more clearly illustrate the specific implementation of the present application or the technical solution in the prior art, the following is a brief introduction to the drawings required for the specific implementation or the prior art description. In all drawings, similar elements or parts are generally identified by similar reference numerals. In the drawings, each element or part is not necessarily drawn according to the actual scale.

[0037] Figure 1 This is the result of identifying the expression level of ELP2 high copy strain;

[0038] Figure 2 This is the result of identifying the expression level of ELP4 and ELP8 high copy strains;

[0039] Figure 3 This is a diagram showing the purification results of recombinant elastin ELP2, ELP4 and ELP8;

[0040] Figure 4 This is the result of identifying the expression level of the repair ELP8-LN-5 high-copy strain;

[0041] Figure 5This is a diagram of the purification results of repair ELP8-LN-5;

[0042] Figure 6 This is the result of the recombinant elastin promoting Hacat cell adhesion activity;

[0043] Figure 7 This is the result diagram of the cell proliferation promoting activity of recombinant elastin;

[0044] Figure 8 This is the result graph of the repair ELP8-LN-5 promoting Hacat cell adhesion and NIH 3T3 cell proliferation activity;

[0045] Fig. 9 This is the result diagram of restorative ELP8-LN-5 promoting Hacat cell migration activity;

[0046] Fig.10 This is a graph showing the changes in wrinkles around the crow's feet after the subjects used the samples;

[0047] Fig.11 This is a graph showing the skin wrinkle area results after the subjects used the samples;

[0048] Fig.12 This is the result graph of the skin elasticity R2 value after the subjects used the samples;

[0049] Fig.13 This is a graph showing the moisture content of the stratum corneum of the skin after the subjects used the samples;

[0050] Fig.14 This is the result graph of the transepidermal water loss (TWEL) value of the skin after the subjects used the samples.

[0051] The realization of the purpose, functional features and advantages of this application will be further explained in conjunction with embodiments and with reference to the accompanying drawings. DETAILED DESCRIPTION

[0052] The following will be combined with the drawings in the embodiments of the present application to clearly and completely describe the technical solutions in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.

[0053] Elastin belongs to the extracellular matrix protein (ECM), which is mainly distributed in tissues and organs such as blood vessels, skin, ligaments and lungs. Elastin can provide sufficient elasticity and resilience, providing tissues with the ability to stretch and restore their original shape. Elastin is a huge, complex, hydrophobic protein. Elastin is not easily degraded by ordinary proteases, but can be degraded by other special proteases, such as matrix metalloproteinases and tissue proteases. Elastin is degraded by chemical means and becomes elastin polypeptide. The soluble precursor of elastin is called tropoelastin. Tropoelastin undergoes self-condensation and cross-linking into an insoluble fishing net structure, called elastin. This makes it very difficult to extract elastin from animal tissues, which requires the decomposition of elastin molecules for release. Each tropoelastin molecule has 36 randomly arranged domains with alternating hydrophobic and hydrophilic domains. The natural elastin extracted from heterologous sources has a certain rejection reaction to the human body, and has the potential risk of carrying pathogens that harm the human body.

[0054] Recombinant elastin is a cyclic repeating amino acid sequence derived from the hydrophobic domain of tropoelastin. It is an artificially modified, elastic, and temperature-dependent genetically engineered polypeptide. Its structure is mainly composed of tandem repeats of VPGⅩG pentapeptide units, and the Xaa guest moiety is any amino acid except proline. Existing studies have shown that this polypeptide sequence has biological activity like tropoelastin, that is, it promotes cell adhesion and cell proliferation, and has the potential to become a new type of biomedical material and biological skin care raw material.

[0055] Laminin (LN) is a member of the macromolecular adhesion glycoprotein family formed by three chains, α, β, and γ, bound by disulfide bonds. It is one of the components of the basement membrane structure. So far, 15 heterotrimers of LN have been known. Among them, laminin-5 (LN-5), which was once named kalinin, epiligrin, and nicein, is the main component protein of the epithelial basement membrane and plays an important role in the stable binding between epithelial cells and the basement membrane. Compared with other known ECMs, LN-5 has a stronger ability to promote cell adhesion, migration, and diffusion. It is currently known that the deformation of the extracellular matrix of the dermis leads to increased wrinkles and decreased elasticity of the skin, and affects the structural and functional changes of the basement membrane between the epidermis and the dermis or skin aging. Among the structural components of the basement membrane, laminin 332 (5) plays an essential role in providing security between the epidermis and the dermis by firmly fixing the epidermis and the dermis.

[0056] Therefore, the present application obtains a repairable elastin by fusing elastin with laminin to promote its cell proliferation, cell adhesion and migration activities, so as to achieve wrinkle removal and repair effects.

[0057] The present application provides a fusion protein of human elastin and laminin expressed by Pichia pastoris, and uses a connecting short peptide linker (GGGGS) to express the elastin pentapeptide repeat sequence and the laminin domain functional region fragment sequence in series. Pichia pastoris expression is endotoxin-free, has a high yield, a simple culture medium, stable expressed protein, and can be secreted to the extracellular space for easy purification. It also has the functions of correctly processing, modifying, and reasonably folding heterologous proteins in space. Therefore, using yeast to express heterologous proteins has great advantages. The fusion protein peptide of the present application has the effects of both elastin and laminin, and has obvious activities in promoting cell proliferation, cell adhesion, and cell migration.

[0058] To facilitate understanding by those skilled in the art, the sequences involved in the technical solution described in this application are listed below:

[0059] SEQ ID No.1:

[0060] VPGKGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGFGVPGKGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGFG-

[0061] SEQ ID No.2:

[0062] VPGKGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGFGVPGKGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGFG VPGKGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGFGVPGKGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGFG-

[0063] SEQ ID No.3:

[0064] VPGKGVPGVG

[0065] SEQ ID No.4:

[0066] GTTCCAGGCAAAGGCGTCCCCGGCGTGGGGGTACCTGGTGTCGGTGTACCCGGTGTCGGTGTCCCTGGCGTCGTGTTTCCGGGTGTTGGCGTACCAGGTGTGGGAGTCCCAGGAGTAGGCTGCCTGGGGTTGGAGTGCCCGGATTTGGAGTGCCGGAAGGGAGTCCCGGGGTTGGGGTTCCCGGGGTGGGTACCCGGAGTAGGCGTACCTGGCGTAGGTGTGCGGGGTTGGAGTTCCAGGAGTGGGAGTACCTGGGGTGGGCTCCAGGTGGGGGTCCGGCTTCGGTTAA

[0067] SEQ ID No.5:

[0068] GTGCCCGGAAAAGGGGTCCCAGGCGTAGGAGTGCCTGGCGTGGGGGTTCCTGGAGTAGGTGTACCAGGAGTCGGAGTCCCAGGCGTTGGGGTCCCGGGGGTTGGTGTGCCTGGCGTCGGAGTCCCCGGTGTGGGGGTTCCGGGATTTGGTGTGCCCGGCAAGGGAGTCCCGGGTGTTGGTGTCCCAGGAGTCGGAGTACCTGGAGTTGGTGTTCCAGGGGTAGGGGTTCCGGGCGTGGGAGTCCCAGGGGTAGGTGTTCCAGGTGTAGGTGTGCCTGGGGTTGGCGTTCCCGGATTCGGTGTGCCCGGTAAAGGTGTCCCGGGCGTGGGGGTTCCGGGAGTGGGAGTCCCTGGCGTGGGAGTGCCTGGCGTAGGCGTGCCGGGTGTAGGGGTACCAGGGGTAGGAGTCCCTGGCGTTGGCGTTCCGGGTGTAGGTGTGCCCGGGTTCGGCGTCCCCGGTAAGGGGGTTCCTGGCGTTGGTGTCCCAGGGGTCGGGGTCCCCGGAGTAGGCGTACCCGGGGTAGGAGTGCCAGGGGTAGGCGTGCCGGGGGTAGGTGTTCCTGGCGTTGGAGTCCCGGGCGTAGGGGTGCCCGGTTTTGGCTAA

[0069] SEQ ID No.6:

[0070]

[0071] SEQ ID No.7:

[0072] CPCPHNSFGMCCVVNGGDVRCSCKAGYGQCERCAPGYFGN PQKFGGSC

[0073] SEQ ID No.8:

[0074] LQGLSASAGLLEQMRHMEQAKDLRNQLLNYRSAISNHGSKIEGLERELDLNQEFELQEKAQVNSRKAQLNNNVNRAQSAKELDVKIKNVIRNVHILLKQISGDGEGNNVPSGDFSREAEAQRMMRELRNRNFGKHLREAEADKRESQLLLNRIRQKHQGENNGLANSIRDSLNEYEAKLSDLRARLQEAAAQAKQANGLNQENERALGAIQRQVKEINSLQSDFKYLADSSLLQNIALQLKEKS

[0075] SEQ ID No.9:

[0076] CPCPHNSFGMCCVVNGGDVRCSCKAGYGQCERCAPGYFGN PQKFGGSCLQGLSASAGLLEQMRHMEQAKDLRNQLLNYRSAISNHGSKIEGLERELDLNQEFELQEKAQVNSRKAQLNNNVNRAQSAKELDVKIKNVIRNVHILLKQISGDGEGNNVPSGDFSREAEAQRMMRELRNRNFGKHLREAEADKRESQLLLNRIRQKHQGENNGLANSIRDSLNEYEAKLSDLRARLQEAAAQAKQANGLNQENERALGAIQRQVKEINSLQSDFKYLADSSLLQNIALQLKEKS-

[0077] SEQ ID No.10:

[0078] -

[0079] SEQ ID No.11:

[0080]

[0081] SEQ ID No.12:

[0082] VPGKGVPGVG

[0083] SEQ ID No.13:

[0084]

[0085] SEQ ID No.14:

[0086] VPGKGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGP

[0087] SEQ ID No.15:

[0088]

[0089] Example 1 Construction and preparation of recombinant elastin strains with different repeat numbers

[0090] 1) Gene sequence selection

[0091] Elastin-like polypeptide is a cyclically repeated amino acid sequence derived from the hydrophobic domain of tropoelastin. It is an artificially modified, elastic, and temperature-dependent genetically engineered polypeptide. Its structure is mainly composed of a series of repeated VPGXG pentapeptide units, and Xaa can be any amino acid except proline.

[0092] The elastin sequence selected in this application is [VPGKG (VPGVG) 8VPGFG] n , the number n is ≥1; wherein n is preferably 2, 4 and 8.

[0093] Step 1): When the number n is 2, the amino acid sequence is SEQ ID No. 1, which has 100aa; a terminator is added to the C-terminus, and the DNA sequence encoding the recombinant elastin is optimized and designed in view of the differences in the transcription and translation processes of genes in different hosts. The corresponding nucleotide sequence is SEQ ID No. 4, so that the recombinant elastin is more easily expressed in Pichia pastoris. The optimized recombinant elastin gene sequence (SEQ ID No. 4) was commissioned to GenScript Biotech Co., Ltd. for gene fragment synthesis. The synthesized gene fragment was passed through Eco R Ⅰ and Not The restriction site of Ⅰ was inserted into the pPIC9K plasmid to obtain the recombinant human elastin recombinant plasmid, which was named pPIC9K-ELP2.

[0094] When n is 4, the amino acid sequence is SEQ ID No.2, which has 200aa. A terminator is added to the C-terminus. In view of the differences in the transcription and translation of genes in different hosts, the DNA sequence encoding the recombinant elastin is optimized and designed. The corresponding nucleotide sequence is SEQ ID No.5, so that the recombinant elastin is more easily expressed in Pichia pastoris. The optimized recombinant elastin gene sequence (SEQ ID No.5) was commissioned to GenScript Biotech Co., Ltd. for gene fragment synthesis. The synthesized gene fragment was passed through Eco R Ⅰ and Not The restriction site of Ⅰ was inserted into the pPIC9K plasmid to obtain the recombinant human elastin recombinant plasmid, which was named pPIC9K-ELP4.

[0095] When n is 8, the amino acid sequence is SEQ ID No.3, which has 400aa. A terminator is added to the C-terminus. In view of the differences in the transcription and translation of genes in different hosts, the DNA sequence encoding the recombinant elastin is optimized and designed. The corresponding nucleotide sequence is SEQ ID No.6, so that the recombinant elastin is more easily expressed in Pichia pastoris. The optimized recombinant elastin gene sequence (SEQ ID No.6) was commissioned to GenScript Biotech Co., Ltd. for gene fragment synthesis. The synthesized gene fragment was passed through Eco R Ⅰ and Not The restriction site of Ⅰ was inserted into the pPIC9K plasmid to obtain the recombinant human elastin recombinant plasmid, which was named pPIC9K-ELP8.

[0096] Step 2): 10 μg of each of the recombinant plasmids pPIC9K-ELP2, pPIC9K-ELP4 and pPIC9K-ELP8 obtained in step 1) were linearized with restriction endonuclease SacⅠ, and then recovered with anhydrous ethanol to obtain linearized recombinant plasmids.

[0097] Take 100 μL of GS115 Pichia competent cells and mix them with the linearized recombinant plasmid, transfer them to a pre-cooled electroporation cup, and immediately place them in an ice bath for 5 min. Select the yeast mode of the electroporator and perform electroporation. Then immediately add 1 mL of pre-cooled 1 M sorbitol to the electroporation cup, mix well, transfer the mixture to a sterile EP tube, and incubate it in a 30 °C incubator for 1h~2 h to obtain a bacterial solution. Take 100 μL~200 μL of the bacterial solution and spread it on an MD solid plate, let it stand at room temperature for 10 min, and invert it in a 30 °C incubator for about 2d~5 d until a single colony appears.

[0098] Step 3): Use a sterile white pipette tip to inoculate the single colonies on the MD plate in step 2) onto YPD solid plates with G418 concentrations of 0.5 mg / mL, 1 mg / mL, 2 mg / mL, 3 mg / mL and 4 mg / mL, respectively. If the transformant can grow on YPD solid plates containing 0.5 mg / mL, 1 mg / mL, 2 mg / mL, 3 mg / mL and 4 mg / mL of G418 at the same time, it means that the transformant contains multiple copies of the target gene. After this step of screening, a high-copy recombinant yeast engineering strain that can express efficiently can be obtained. Experiments have shown that GS115 / pPIC9K-ELP 2 、 Both GS115 / pPIC9K-ELP4 and GS115 / pPIC9K-ELP8 can grow on plates with a high concentration of 4 mg / mL G418, that is, they are both high-copy recombinant strains.

[0099] Step 4): Pick four single colonies of high-copy recombinant strains GS115 / pPIC9K-ELP2, GS115 / pPIC9K-ELP4 and GS115 / pPIC9K-ELP8 and inoculate them into BMGY medium. Cultivate at 30 ºC and 220 rpm for 24 h until the OD value is 2-6. Adjust the volume of BMGY culture solution according to the measured OD value, collect the bacteria at 3000 rpm for 10 min, and resuspend the bacteria with an equal volume of BMMY medium to make the initial OD value 2.0. Continue to cultivate at 30 ºC and 220 rpm, add 0.5% methanol to the culture medium every 24 h, and take bacterial samples 96 h after methanol induction, and collect the expression supernatant by centrifugation. The expression of the recombinant strains was analyzed by SDS-PAGE electrophoresis, and the expressed target proteins were named ELP2 (molecular weight 8.36kD), ELP4 (molecular weight 16.70kD) and ELP8 (molecular weight 33.30kD). The expression identification results are shown in Figure 1 and Figure 2 .

[0100] Step 5): Use a cation exchange medium (chromatographic filler is SP Sanarose 6 HP produced by Xiamen Sanji, loaded on a GE Akta chromatography system), and balance the column with citrate buffer (20Mm, pH 5.0) until the conductivity value and A280 absorbance value remain unchanged. Set the sample loading flow rate to 5 mL / min, detect the UV A280 absorbance value, and start sampling when it rises. After the loading is completed, balance the cationic chromatography medium with citrate buffer until the UV and conductivity drop to the minimum and no longer change, and the balance is completed. Then elute with citrate buffer containing NaCl (500mM) and collect the corresponding proteins to obtain recombinant elastin ELP2, ELP4 and ELP8 (such as Figure 3 ).

[0101] Experimental Example 1

[0102] The Hacat cell adhesion promoting activities of the recombinant elastin ELP2, ELP4 and ELP8 described in Example 1 were tested respectively:

[0103] Dilute to 0.5 μg / mL with 20 mM pH 7.4 PBS solution, perform 2-fold gradient dilution in a 96-well plate, make 10 dilutions in total, 50 μL of different dilutions in each well, test each sample in parallel three times, use 20 mM PBS as negative control, set commercial elastin (purchased from Solebo, P06063) as positive control, and incubate at 4°C overnight. After incubation, discard the liquid in the plate, add 100 μL 30 g / L BSA to each well for blocking, and incubate in a 37°C incubator for 1 hour; remove and discard the liquid in the plate, add human skin immortalized keratinocytes Hacat in the logarithmic growth phase, and add 1.0×10 5 / mL, 100μL per well, incubate at 37℃ for 5h. Wash the incubated cell plate 3 times with 20mM PBS, observe the cell adhesion under a microscope, select five points except the edge under a 200x microscope to count the number of adherent cells, and calculate the titer based on the four-parameter fitting curve of the counting results.

[0104] The results are shown in Table 1 and Figure 6 As shown, it can be seen that the recombinant elastin prepared in Example 1 of the present application has a significantly higher effect on promoting Hacat cell adhesion than commercial elastin, and as the number of cycles n increases, the activity of promoting cell adhesion increases, with n being 8 being the highest activity.

[0105] Table 1 Recombinant elastin promotes Hacat cell adhesion activity

[0106]

[0107] Experimental Example 2

[0108] The proliferative activity of the recombinant elastin ELP2, ELP4 and ELP8 described in Example 1 in promoting NIH 3T3 cells was tested respectively:

[0109] Refer to Appendix "3528" of the 2020 edition (Part III) of the Chinese Pharmacopoeia. This method is based on the fact that recombinant elastin has a stimulating effect on the growth of mouse embryonic fibroblasts (BALB / c 3T3 cells). The growth of NIH 3T3 cells varies due to the different biological activities of different recombinant elastins, so as to detect the biological activity of promoting cell proliferation in vitro.

[0110] 1.1 Test materials:

[0111] Complete cell culture medium: 1640 culture medium (containing penicillin-streptomycin) with 10% fetal bovine serum, stored at 4°C; serum-free medium: 1640 culture medium (containing penicillin-streptomycin), stored at 4°C; digestion solution: 0.25% trypsin; MTT solution: weigh 0.10 g of MTT powder, add 20 mL of PBS to dissolve, filter through a 0.22 μm filter membrane to sterilize, and store at 4°C in the dark; NIH 3T3 cells (purchased from Wuhan Punosai);

[0112] Samples: the recombinant elastin of Example 1, commercial elastin (purchased from Solebol, P06063).

[0113] 1.2 Specific implementation methods:

[0114] NIH 3T3 cell line was cultured in complete cell culture medium at 37°C and 5% carbon dioxide, and the cell concentration was controlled to be 5.0×10 5 / mL, and used for biological activity determination 24h-36h after subculture; discard the culture medium in the culture flask, digest and collect the cells, and use complete cell culture medium to make 5.0×10 5 / mL cell suspension, inoculated in a 96-well cell culture plate, 100μL per well, cultured at 37℃, 5% carbon dioxide; after 24h, replaced with 20mM PBS buffer, cultured at 37C, 5% carbon dioxide for 24h; discarded PBS buffer from the prepared cell culture plate, added test solution, 100μL per well, cultured at 37℃, 5% carbon dioxide for 64h-72h; added 20μL MTT solution to each well, cultured at 37℃, 5% carbon dioxide for 5h. After discarding the liquid in the culture plate, add 100μL DMSO to each well, mix well, and measure the absorbance at 570nm on a microplate reader with 630nm as the reference wavelength, and record the measurement results.

[0115] 1.3 Data processing:

[0116] The test data were processed using a computer program or a four-parameter regression calculation method. The test results are shown in Table 2 and Figure 7 As shown, it can be seen that the recombinant elastin prepared in Example 1 of the present application has a significantly higher effect on promoting NIH 3T3 cell proliferation than commercial elastin, and the cell proliferation activity increases with the increase of n cycle number, wherein n is 8 and the activity is the highest.

[0117] Table 2 Cell proliferation promoting activity of recombinant elastin

[0118]

[0119] Example 3

[0120] Based on the experimental results of Experimental Example 1 and Experimental Example 2, it can be seen that the recombinant elastin ELP8 has the highest activity in promoting Hacat cell adhesion and NIH 3T3 cell proliferation, that is, the anti-wrinkle effect is the most obvious. Therefore, laminin (LN) is linked to a flexible linker (GGGGS) 3~5 , linker (GGGGS) 3 is preferentially selected and connected to the N-terminus or C-terminus of the recombinant elastin ELP8, with the C-terminus being preferred.

[0121] 1) Selection of LN-5 gene sequence

[0122] Compared with other known ECMs, LN-5 has a stronger ability to promote cell adhesion, migration and proliferation. The gene accession number of the α3 chain of LN-5 was searched in the NCBI database (CAA59428.1). The gene sequence 114-164 region was selected, which was EGF_Lam, SEQ ID No.7. The gene sequence 227-484 region was selected, which was Laminin_I, SEQ ID No.8. The laminin sequence was obtained by concatenation, SEQ ID No.9.

[0123] The laminin sequence SEQ ID No. 9 is connected to the N-terminus of the recombinant elastin ELP8 via a flexible linker (GGGGS) 3, which is the repair recombinant elastin sequence, SEQ ID No. 10.

[0124] A terminator is added to the C-terminus, and the DNA sequence encoding the reparative recombinant elastin is optimized and designed in view of the differences in the transcription and translation processes of the gene in different hosts. The nucleotide sequence is SEQ ID No. 11, which makes it easier to express the reparative recombinant elastin in Pichia pastoris.

[0125] The optimized recombinant resilin-like gene sequence SEQ ID No.11 was commissioned to GenScript Biotech Co., Ltd. to synthesize the gene fragment. Eco R Ⅰ and Not The restriction site of Ⅰ was inserted into the pPIC9K plasmid to obtain the recombinant plasmid of repair recombinant human elastin, named pPIC9K-ELP8-FN-5 (molecular weight 62.0kD).

[0126] According to the method of Example 1, a recombinant strain expressing recombinant human elastin was constructed, a high copy strain was screened, and recombinant elastin was prepared, and the final product was named ELP8-LN-5 fusion protein. Figure 4 This is the result of identification of the expression level of the high-copy strain of the recombinant elastin ELP8-LN-5. Figure 5The figure shows the purification result of ELP8-LN-5 fusion protein.

[0127] Experimental Example 3 Repair recombinant protein promotes cell adhesion and proliferation activity

[0128] According to the test methods of Experimental Examples 1 and 2, the ELP8-LN-5 fusion protein prepared in Example 2 was tested, and the recombinant elastin ELP8 prepared in Example 1 was used as a control, and the negative control was the PBS group. The activities of the ELP8-LN-5 fusion protein and the recombinant elastin ELP8 were compared. The test results are shown in Table 3.

[0129] Table 3 Restorative ELP8-LN-5 promotes Hacat cell adhesion and NIH 3T3 cell proliferation activity

[0130]

[0131] From Table 3 and Figure 8 As shown, the ELP8-LN-5 fusion protein prepared in Example 2 of the present application has significantly higher Hacat cell adhesion activity and NIH 3T3 cell proliferation effect than the recombinant elastin ELP8 prepared in Example 1, which indicates that elastin fusion with laminin can significantly improve its cell adhesion activity and proliferation activity.

[0132] Experimental Example 4 ELP8-LN-5 fusion protein promotes Hacat cell migration activity

[0133] The specific method is as follows:

[0134] 1) Use a black marker pen to align the ruler on the back of the 6-well cell culture plate and draw horizontal lines evenly, approximately every 0.5 cm to 1 cm, across the holes;

[0135] 2) Collect Hacat cells in the logarithmic growth phase and adjust the cell density to 5×10 5 / mL, 2mL / well, added to the above 6-well cell plate, placed in a 37℃ 5% carbon dioxide incubator for 24h, until the cells grew into a full monolayer, use the gun tip to compare with the ruler, and scratch perpendicular to the horizontal line on the back, draw 2 horizontal lines in each well, wash the cells 3 times with PBS, wash off the scratched suspended cells, and then add 1.8mL of serum-free DMEM medium to the wells.

[0136] 3) ELP8-LN-5 fusion protein and recombinant elastin ELP8 were added to the wells, and commercial ELP (same as above) was used as a positive control group. The above protein concentrations were all 50 μg / mL, and PBS was used as a blank control group.

[0137] 4) Place the 6-well cell plate with the sample to be tested in a 37℃ 5% carbon dioxide incubator for 24 hours. Take a photo at the 0th hour of incubation and record the photo position in each well. At the 24th hour of incubation, observe and take photos of the fixed position. Use Image J software to process the pictures of cell migration, obtain the initial scratch area and the area of ​​the cell-free blank area, and calculate the migration rate. Among them, migration rate = cell-free blank area / initial scratch area × 100%.

[0138] Observation results of cell control wells and each sample well at 0h and 18h Fig. 9 And the effect of each treatment group on promoting the migration of HaCaT keratinocytes was calculated.

[0139] Compared with commercial ELP, the recombinant elastin ELP8 invented in this patent has similar effects in promoting HaCat cell migration, and is significantly different from the negative control; the ELP8-LN-5 fusion protein has the highest activity, indicating that ELP8 fused with laminin can increase the migration-promoting activity of elastin to 74%.

[0140] Experimental Example 5: Human skin efficacy evaluation of ELP8-LN-5 fusion protein.

[0141] 1) Anti-wrinkle effect test of ELP8-LN-5 fusion protein on human skin

[0142] The ELP8-LN-5 fusion protein prepared in Example 2 was prepared into an ELP8-LN-5 fusion protein essence sample, and 30 Asian adult female subjects used the ELP8-LN-5 fusion protein essence sample continuously for 28 days under normal conditions. The wrinkle area of ​​the crow's feet and the R2 value of skin elasticity were measured. In addition, dermatologists conducted efficacy clinical evaluation and safety clinical evaluation on the subjects to evaluate the anti-wrinkle efficacy and safety of the test sample.

[0143] 1.1 Specific implementation methods:

[0144] Before using the samples: two days before the test, the subjects stopped using cosmetics or external medicines. The night before the test, the subjects did not apply any skin care products on their faces after washing their faces. On the morning of the test, the subjects did not apply any skin care products on their faces after washing their faces with clean water. The subjects rested for 30 minutes in an environment with a temperature of 21±1℃ and a relative humidity of 50±10%RH. Dermatologists conducted clinical evaluations. Technicians used the skin rapid optical imaging system PRIMOS to capture images of the subjects. Technicians used the skin elasticity tester Cutometer to detect the skin elasticity R2 value and the skin wrinkle area of ​​the crow's feet around the eyes. The subjects used the test samples under the guidance of the technicians. The test samples and instructions for use were distributed.

[0145] After using the samples for 14 days and 28 days respectively: the subjects cleansed their faces with a cleansing product in the laboratory; the subjects rested for 30 minutes in an environment with a temperature of 21±1℃ and a relative humidity of 50±10%RH; technicians used the skin rapid optical imaging system PRIMOS to capture images of the subjects; technicians used the skin elasticity tester Cutometer to detect the skin elasticity R2 value and the skin wrinkle area in the crow's feet area of ​​the eyes.

[0146] 1.2 Judging basis:

[0147] Skin elasticity: Courage+ Khazaka Skin Elasticity Tester detects the skin elasticity R2 value. An increase in the measured value indicates improved skin elasticity.

[0148] Skin wrinkle area (crow's feet): Courage Skin Rapid Optical Imaging System PRIMOS is used to detect skin wrinkle area. The smaller the value, the smaller the wrinkle volume.

[0149] 1.3 Data processing

[0150] The statistical software was used to analyze the differences between the 14th and 28th day after using the restorative recombinant elastin serum and before use. Fig.11 and Fig.12 "*" indicates that the skin elasticity R2 value and skin wrinkle area are significantly different from before use. P <0.05.

[0151] Depend on Fig.10 As shown in the figure, after the subjects used the ELP8-LN-5 fusion protein essence for 14 days, the area and number of wrinkles on the eye skin decreased, and the depth of wrinkles became shallower. Especially on the 28th day, the anti-wrinkle effect was particularly obvious. After data statistics, it can be seen that Fig.11 As shown in the figure, at 14th and 28th days of use, the crow's feet wrinkle area was significantly reduced compared with before use, with significant differences. Fig.12 As shown, the skin elasticity R2 value on the 14th day of use was improved to a certain extent compared with that before use, but the difference was not significant, while the skin elasticity R2 value on the 28th day of use was significantly improved, and the difference was significant. It can be seen that the ELP8-LN-5 fusion protein prepared in this application has a good anti-wrinkle effect.

[0152] 2) ELP8-LN-5 fusion protein repair effect on human skin

[0153] The ELP8-LN-5 fusion protein prepared in Example 2 was prepared into ELP8-LN-5 fusion protein essence. 26 healthy adult subjects used the ELP8-LN-5 fusion protein essence sample continuously for 28 days under normal conditions to detect the transepidermal water loss TEWL value and the water content of the skin stratum corneum.

[0154] 2.1 Specific implementation methods:

[0155] Before using the sample: Two days before the test, the subjects stopped using cosmetics or topical drugs. The night before the test, the subjects did not apply any skin care products on their faces after washing their faces. On the morning of the test, the subjects did not apply any skin care products on their faces after washing their faces with water. The subjects rested for 30 minutes in an environment with a temperature of 21±1℃ and a relative humidity of 50±10%RH. The technicians used the skin water loss test probe TewameterTM300 to detect the transepidermal water loss TEWL value of the skin and the skin moisture meter CorneometerCM825 to detect the moisture content of the skin stratum corneum. The subjects used the test samples under the guidance of the technicians; the test samples and instructions for use were distributed.

[0156] After using the samples for 14 days and 28 days respectively: the subjects cleaned their faces with a cleansing product in the laboratory; the subjects rested for 30 minutes in an environment with a temperature of 21±1℃ and a relative humidity of 50±10%RH; the skin water loss test probe TewameterTM300 was used to detect the transepidermal water loss TEWL value of the skin; technicians used the skin moisture meter CorneometerCM825 to detect the moisture content of the skin stratum corneum.

[0157] 2.2 Judging basis:

[0158] Water content of the skin stratum corneum: CorneometerCM825 skin moisture tester detects the water content of the skin stratum corneum. The larger the measured value, the higher the water content of the skin stratum corneum.

[0159] Transepidermal water loss: The skin water loss test probe TewameterTM300 detects the TEWL value of the skin. The smaller the measured value, the less the transepidermal water loss per unit time and unit cross-sectional area.

[0160] 2.3 Data processing

[0161] After statistical software analysis, the differences between the 14th and 28th day after using the ELP8-LN-5 fusion protein essence and before use were compared. Fig.13 and Fig.14 "*" indicates that the skin elasticity R2 value and skin wrinkle area are significantly different from before use. P <0.05.

[0162] Depend on Fig.13 As shown, the water content of the stratum corneum of the subjects' skin increased significantly after using the ELP8-LN-5 fusion protein essence for 14 and 28 days, and the difference was significant. Fig.14As shown in the figure, the transepidermal water loss (TWEL) value of the skin was significantly reduced at 14 days and 28 days after use, and the difference was significant. It can be seen that the ELP8-LN-5 fusion protein prepared in Example 2 has moisturizing and repairing effects.

[0163] In summary, the present application provides a fusion protein of human elastin and laminin expressed by Pichia pastoris, and uses a connecting short peptide linker (GGGGS) to express the elastin pentapeptide repeat fragment sequence and the laminin domain functional region fragment sequence in series. Pichia pastoris expression is endotoxin-free, has a high yield, a simple culture medium, stable expressed protein, and can be secreted to the extracellular space for easy purification. It also has the functions of correctly processing, modifying, and reasonably folding heterologous proteins. Therefore, using yeast to express heterologous proteins has great advantages. In addition, the present application uses genetic engineering technology to recombinantly express laminin functional fragments and elastin domain fragments to obtain a repairable elastin. After in vitro cell verification and human efficacy verification, the repairable elastin has the effects of laminin and elastin at the same time, and has significantly improved cell proliferation, cell adhesion and cell migration activity. It can be applied to the field of biological skin care and has obvious anti-wrinkle repair effects.

[0164] The above are only preferred embodiments of the present application, and are not intended to limit the patent scope of the present application. Any equivalent structure or equivalent process transformation made using the contents of the present application specification and drawings, or directly or indirectly applied in other related technical fields, are also included in the patent protection scope of the present application.

Claims

1. An elastin-like protein having both repair and anti-wrinkle activities, characterized in that: The elastin-like protein with both repair and anti-wrinkle activities is obtained by connecting laminin to the C-terminus of the original elastin-like protein through a flexible linker; the protein sequence of the laminin is shown in SEQ ID No.9; When the nucleotide sequence of the initial elastin-like protein is expressed as shown in SEQ ID No.6, the amino acid sequence of the elastin-like protein having both repair and anti-wrinkle activities is shown in SEQ ID No.

10.

2. An elastin-like protein having both repair and anti-wrinkle activities, characterized in that: The amino acid sequence of the elastin-like protein having both repair and anti-wrinkle activities is shown in SEQ ID No.

12.

3. An elastin-like protein having both repair and anti-wrinkle activities, characterized in that: The amino acid sequence of the elastin-like protein having both repair and anti-wrinkle activities is shown in SEQ ID No.

14.

4. A method for preparing an elastin-like protein having both repair and anti-wrinkle activities as claimed in any one of claims 1 to 3, characterized in that: The following steps are involved: Optimizing and designing the amino acid sequence of the elastin-like protein having both repair and anti-wrinkle activities as described in any one of claims 1 to 3 to obtain the corresponding nucleotide sequence; Based on the nucleotide sequence, a recombinant plasmid of reparative recombinant human elastin is obtained, the recombinant plasmid of reparative recombinant human elastin is subjected to Pichia pastoris electroporation, and cultured until a single colony appears, and a high-copy recombinant yeast engineering strain is obtained by screening; the high-copy recombinant yeast engineering strain is induced to express, and the expression target protein is obtained; the expression target protein is purified to obtain an elastin-like protein with both repair and anti-wrinkle activities.

5. A use of the elastin-like protein having both repair and anti-wrinkle activities as claimed in any one of claims 1 to 3, characterized in that: The elastin-like protein having both repair and anti-wrinkle activities is used to prepare skin care products; The skin care product prepared from the elastin-like protein having both repair and anti-wrinkle activities has a specific activity of 28500 U / mg in promoting Hacat cell adhesion.

6. A use of the elastin-like protein having both repair and anti-wrinkle activities as claimed in any one of claims 1 to 3, characterized in that: The skin care product prepared from the elastin-like protein having both repair and anti-wrinkle activities has a cell proliferation promoting specific activity of 59500 U / mg.

7. A use of the elastin-like protein having both repair and anti-wrinkle activities as claimed in any one of claims 1 to 3, characterized in that: The skin care product prepared from the elastin-like protein having both repair and anti-wrinkle activities has a Hacat cell migration promoting activity of 46.40%.